丽珠医药集团收购越南IMP公司股权进展公告详细解读

要点摘要

• 丽珠医药集团（证券代码：000513、01513）通过其境外全资子公司 LIAN SGP HOLDING PTE. LTD.，已完成对越南上市公司 Imexpharm Corporation（IMP）的公开要约收购。
• 此次收购要约的价格为每股57,400越南盾（约合人民币15.37元/股，最终收购结果日按汇率约合人民币15.62亿元），要约收购股份上限为120,059,970股，占IMP注册资本的77.94%。
• 公开要约收购已于公告日结束，最终丽珠集团通过LIAN SGP持有IMP 104,545,781股，占IMP注册资本的67.87%，占表决权股份的67.88%。
• 收购价款总额为6,000,927,829,400越南盾（约15.62亿元人民币）。
• 后续将推进股份收购价款支付及股份交割程序。
• 项目仍存在一定不确定性，受市场变化及后续审批等影响。

详细内容

2025年5月22日，丽珠医药集团董事会审议通过了收购越南IMP公司股权的议案，并由境外全资子公司LIAN SGP与SK Investment Vina III Pte. Ltd.、Sunrise Kim Investment Joint Stock Company及KBA Investment Joint Stock Company等卖方签署了《框架协议》。由于收购触发了越南证券的公开要约规定，LIAN SGP向IMP所有股东发出收购要约。

2025年12月30日，董事会再次审议通过公开要约收购议案，授权LIAN SGP按照越南国家证券委员会要求申请公开要约收购IMP股份。收购股份上限为120,059,970股，占IMP注册资本的77.94%，收购价格为每股57,400越南盾。

2026年3月6日，LIAN SGP收到越南国家证券委员会同意本次交易的批复。此后，公开要约收购正式启动并于公告日结束。

最终，LIAN SGP持有IMP 104,545,781股股份，占IMP注册资本的67.87%，表决权股份的67.88%。收购价款总额为6,000,927,829,400越南盾，折合人民币约15.62亿元。交易完成后，丽珠集团将成为IMP的控股股东，有望进一步扩展其在东南亚医药市场的影响力。

公开要约结束后，丽珠集团将继续推进股份收购价款支付及股份交割程序。公司提示，本次交易仍受市场变化和后续审批等因素影响，存在一定不确定性。

对股东和投资者的影响

• 丽珠集团收购IMP超过67%的股份，成为控股股东，意味着公司在越南医药市场的重要布局，长期有望提升业绩和市场地位。
• 收购金额高达15.62亿元人民币，显示公司资金实力和战略决心。
• 交易进展顺利，但后续交割和支付仍存在不确定性，投资者需关注未来相关公告。
• 本次交易的成功有望对丽珠集团股价带来积极影响，但也需留意交易风险及市场波动。

风险提示

• 交易仍需完成后续支付及股份交割，存在审批和市场变化的不确定性。
• 公司将严格遵守相关法律法规和信息披露义务，投资者需关注后续公告。

结论

丽珠医药集团对越南IMP公司控股收购是公司国际化战略的重要一步，交易金额巨大，控股比例高，短期和长期均可能对公司股价产生重大影响。投资者需密切关注后续进展与风险提示。

免责声明

本文章仅为信息解读，内容不构成投资建议。投资者应根据自身情况和风险承受能力谨慎决策，关注公司后续公告及监管信息。

English Version

Detailed Interpretation: Livzon Pharmaceutical Group’s Progress on Acquiring Vietnam IMP Shares

Key Points Summary

• Livzon Pharmaceutical Group (stock codes: 000513, 01513), via its wholly owned overseas subsidiary LIAN SGP HOLDING PTE. LTD., has completed a public offer to acquire shares of Vietnamese listed company Imexpharm Corporation (IMP).
• The offer price was VND 57,400 per share (approximately RMB 15.37 per share, and RMB 1.562 billion in total at the final exchange rate). The maximum number of shares offered was 120,059,970, equivalent to 77.94% of IMP’s registered capital.
• The offer period has ended; Livzon now holds 104,545,781 IMP shares, representing 67.87% of IMP’s registered capital and 67.88% of voting shares.
• Total transaction consideration is VND 6,000,927,829,400 (about RMB 1.562 billion).
• Next steps include payment and share transfer procedures.
• There is still uncertainty due to market changes and subsequent approvals.

Full Details

On May 22, 2025, Livzon’s board approved the acquisition plan for IMP shares. LIAN SGP signed a Framework Agreement with multiple sellers. The deal triggered Vietnam’s public offer requirements, and LIAN SGP issued a public offer to all IMP shareholders.

On December 30, 2025, the board approved the public offer plan, allowing LIAN SGP to apply to Vietnam’s State Securities Commission. The offer was for up to 120,059,970 shares at VND 57,400 per share.

On March 6, 2026, LIAN SGP received approval from Vietnam’s State Securities Commission. The public offer then officially commenced and has now ended.

LIAN SGP ultimately acquired 104,545,781 shares, representing 67.87% of IMP’s registered capital and 67.88% of voting shares. The total consideration was VND 6,000,927,829,400 (about RMB 1.562 billion). Livzon will become the controlling shareholder, strengthening its position in Southeast Asia’s pharmaceutical market.

Following the offer, Livzon will proceed with payment and share transfer procedures. The company warns there is still uncertainty due to market changes and further approvals.

Implications for Shareholders and Investors

• Livzon’s acquisition of more than 67% of IMP shares means it becomes the controlling shareholder, marking a significant step in its Southeast Asia strategy, potentially boosting performance and market position long-term.
• The deal’s size (RMB 1.562 billion) demonstrates Livzon’s financial capacity and strategic commitment.
• While progress is positive, payment and share transfer are pending and subject to uncertainty, so investors should monitor further announcements.
• This deal could positively affect Livzon’s share price, but attention to transaction risks and market volatility is warranted.

Risk Warning

• The deal is still subject to completion of payment and share transfer, with approval and market uncertainties remaining.
• Livzon will comply with all legal and disclosure requirements; investors should follow subsequent announcements.

Conclusion

Livzon’s controlling acquisition of IMP is a major step in its international strategy, with substantial deal size and high controlling ratio, likely to impact the share price both short and long term. Investors should closely monitor follow-up developments and risk warnings.

Disclaimer

This article is for informational interpretation only and does not constitute investment advice. Investors should make decisions based on their own circumstances and risk tolerance, and pay attention to subsequent company announcements and regulatory information.

View 丽珠集团 Historical chart here